Because these are prescription medicines a consultation is required to ensure that a GLP-1 is suitable for you. The consultation includes checking your medical history, current medicines, and recent lab results. We also take some body measurements, and discuss your goals.
There is currently no government funding for Wegovy or Mounjaro so you will asked to pay the full price for the medicine. A consultation fee also applies.
There are a variety of dose strengths and the price varies according to which strength you are using.
If you have any questions feel free to call us on 06-358-7788
GLP-1 agonists (GLP-1s) are medicines that mimic a natural gut hormone called glucagon-like peptide-1. GLP-1s slow stomach emptying, reduce 'food noise', and increase feelings of fullness which reduces appetite. They are particularly useful in people who struggle with weight management and have a BMI greater than 30. GLP-1s also work by helping the body control blood sugar levels. Tirzepatide works similarly, but it stimulates both GIP and GLP-1 receptors rather than GLP-1 alone. GIP agonists increase insulin release, as well as working in the brain to decrease appetite and increase feelings of fullness. This is similar to GLP-1 agonists, and it appears simulating both GLP-1 and GLP receptors has an additive effect. (Tirzepatide Tops Semaglutide for Weight Loss - Medscape, Mounjaro Patient Information , Wegovy Patient Information)
The main benefits of GLP-1s are improved glucose control, weight loss, and, in some cases, a lower risk of major cardiovascular events in people at increased risk. However, they also have risks. The most common side effects are nausea, vomiting, diarrhoea, constipation, and abdominal pain. (FDA Access Data)
Semaglutide and tirzepatide are both once-weekly injectable medicines that can improve blood sugar control and support weight loss, but they are not the same. Semaglutide has a longer clinical track record and strong evidence for cardiovascular benefit in both diabetes and obesity populations. Tirzepatide has shown greater average reductions in HbA1c (longer term blood sugar levels) and body weight in head-to-head trials against semaglutide, but it has a similar pattern of stomach-related side effects. Semaglutide may suit people who value its longer evidence base, while tirzepatide may suit people who prioritise stronger average effects on weight and glucose control. The best choice depends on the your personal health goals, other medical conditions, side-effect tolerance, availability, and cost. (New England Journal of Medicine)
References
We’re a small family run Pharmacy in Palmerston North. We pride ourselves on looking after our patients and customers needs. If you need health and well being advice for yourself, or your family feel free to drop in and talk to one of our staff.
